Pilot Study of Rituximab for the Treatment of Acute Immune Thrombocytopenic Purpura (ITP)

NCT00372892 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Purpura, Thrombocytopenic, Idiopathic

Interventions

DRUG: Rituximab
DRUG: Placebo

Sponsor

Hamilton Health Sciences Corporation

Collaborators

[object Object]